The Royal Court of Jersey sanctioned Shire’s proposed acquisition of Takeda Pharmaceuticals.
Exact Sciences expects to post fourth quarter 2018 revenues between $142.5 million to $143.5 million, a 64 percent year-over-year increase.
EnteraSense secured $4 million in funding for its gastrointestinal tract bleed-detecting capsule.
Landos Biopharma reported results from its phase 1 trial of BT-11, an ulcerative colitis and Crohn’s disease treatment.
More articles on gastroenterology:
5 thoughts on Cologuard, gastroenterology’s future & the tax threatening Connecticut ASCs from Dr. Charles Adelmann
Landos’ IBD drug well-tolerated — 6 study insights
EnteraSense secures $4M in funding for bleed-detecting GI tract capsule — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
